E. Garaci – författare

The 2nd International Symposium on Combination Therapies brought together several hundred of the leading researchers, scientists and clinicians in this area to discuss new and emerging uses for biological response modifiers (BRM's) in the treatment of cancer and infectious diseases. The meeting was held during May 1-3, 1992 in Acireale, Sicily (Italy). It was hosted by Professor G. Nicoletti CU. of Catania) and organized by the Institute for Advanced Studies in Immunology and Aging (Washington, D. C. ) in collaboration with the University of Rome "Tor Vergata," the University of Catania and The George Washington University Medical Center. The synergy exhibited between BRM's and conventional therapies including bone marrow and other lymphoid cell transplants is a rapidly expanding area with significant promise for the treatment of human diseases. Advances in this area of biomedicine are leading to the rapid development of new therapeutic approaches that are being applied clinically as both primary and adjuvant therapy to enhance the effectiveness of conventional treatments. The 2nd International Symposium on Combination Therapy provided a setting for the exchange of new scientific information regarding the emerging uses for BRM's alone or in combination with conventional therapies. The 1st International Symposium on Combination Therapies was held in 1991 in Washington, D. C.

Over the past decade many of the key lymphokines, hormones and growth factors that help regulate the immune system have been defined. These molecules, termed biological response modifiers (BRMs) , have been sequenced, synthesized and produced in large enough quantities to test in animals and humans resulting in the development of new approaches to the treatment of human disease, in particular, cancers and infectious diseases. Advances in this area have also led to rethinking therapies against a range of autoimmune disorders and other diseases associated with immune and endocrine imbalances. BRMs currently are being applied clinically as both primary and adjunctive therapy to enhance the effectiveness of traditional treatments by maximizing their activities and to protect critical tissues against intolerable chemotherapeutic and radiation damage. Present constraints against the use of BRMs revolve around the nature of these substances in vivo, where many of their actions and the majority of their interactions and synergies remain to be elucidated. For example, as these molecules are thought to exert their effects locally, the systemic administration of lymphokines, cytokines and growth factors at doses adequate to produce a wanted anti-tumor effect in many instances is intolerably toxic. Efforts to overcome this formidable problem have led scientists to begin to explore the transfer of genes known to encode for these molecules into cells which otherwise inadequately elicit or produce anti-tumor or anti-infective responses.

The 2nd International Symposium on Combination Therapies brought together several hundred of the leading researchers, scientists and clinicians in this area to discuss new and emerging uses for biological response modifiers (BRM''s) in the treatment of cancer and infectious diseases. The meeting was held during May 1-3, 1992 in Acireale, Sicily (Italy). It was hosted by Professor G. Nicoletti CU. of Catania) and organized by the Institute for Advanced Studies in Immunology and Aging (Washington, D. C. ) in collaboration with the University of Rome "Tor Vergata," the University of Catania and The George Washington University Medical Center. The synergy exhibited between BRM''s and conventional therapies including bone marrow and other lymphoid cell transplants is a rapidly expanding area with significant promise for the treatment of human diseases. Advances in this area of biomedicine are leading to the rapid development of new therapeutic approaches that are being applied clinically as both primary and adjuvant therapy to enhance the effectiveness of conventional treatments. The 2nd International Symposium on Combination Therapy provided a setting for the exchange of new scientific information regarding the emerging uses for BRM''s alone or in combination with conventional therapies. The 1st International Symposium on Combination Therapies was held in 1991 in Washington, D. C.